ClinicalTrials.gg
RecruitingNCT07578116Updated Oct 13, 2026

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

A Phase 3 interventional study of Biopsy Procedure and Biospecimen Collection in Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma and Oligometastatic Breast Carcinoma, sponsored by SWOG Cancer Research Network. Recruiting at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by SWOG Cancer Research Network · Phase 3, Interventional, and Treatment

How we know · 19 judgments

Updated Oct 13, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
562
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Planned enrollment
33rd of 366
562 · median 61
Started
2027
with 1 other
Phase 3
60 of 374
3 open now
Primary completion
2032-05
later than 84 of 85 live
Registered
370th of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 33rd largest by planned enrollment of the 366 interventional ones that give a count, is one of 2 that started in 2027, is one of 60 in phase 3, reaches primary completion later than 84 of the 85 other live ones, and was the 370th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with HER2-positive stage IV breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or to a limited number of sites (oligometastatic). The usual approach for patients with (oligo)metastatic HER2-positive breast cancer is systemic drug treatment, which means medicines that travel through the whole body to treat both the breast and any areas where the cancer has spread. There are a number of approved HER2-targeted systemic therapy regimens available to patients. These typically include immunotherapy and/or chemotherapy. Immunotherapy drugs may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Unlike systemic therapy, locoregional therapies like surgery and radiation are focused treatments at the site of disease, delivered with the intent of sparing healthy tissues. Breast surgeries such as breast conserving therapy or total mastectomy are procedures in which the cancerous breast tissue (and healthy breast tissue in the case of total mastectomy) are surgically removed from the body. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Adding locoregional therapy, as well as metastasis-directed SBRT, to standard systemic therapy may help patients with (oligo)metastatic, HER2-positive stage IV breast cancer live longer overall or before their cancer progresses, and may help more patients achieve no evidence of disease, when compared to standard systemic therapy alone.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare overall survival (OS) between participants with de novo stage IV oligometastatic HER2+ breast cancer who experience at least a partial response (PR) after initial systemic therapy similar to those used in stage III disease with curative intent, and are randomized to a multimodality approach including definitive locoregional therapy with surgery and radiotherapy and ablative intent stereotactic radiotherapy to detectable metastatic lesions followed by additional HER2-directed systemic therapy, similar to those used for residual disease after neoadjuvant therapy, (Cohort A, Arm 1) versus those who are randomized to physician's choice standard of care HER2-directed systemic therapies without local and metastasis directed ablative therapies (Cohort A, Arm 2). (Randomized Cohort A) II. To evaluate the distribution of progression-free survival (PFS) and overall survival (OS) among participants with de novo stage IV oligometastatic HER2+ breast cancer who do not experience a response after systemic therapy. (Observational Cohort B)

SECONDARY OBJECTIVES:

I. To compare progression-free survival (PFS) in Cohort A, Arm 1 (randomized to multimodality therapy) versus Cohort A, Arm 2 (randomized to standard of care HER2-directed systemic therapy). (Randomized Cohort) II. To compare PFS in Cohort A, Arm 1 per protocol (received all multimodality therapy as planned) versus Cohort A, Arm 2. (Randomized Cohort) III. To compare OS in Cohort A, Arm 1 per protocol (received all multimodality therapy as planned) versus Cohort A, Arm 2. (Randomized Cohort) IV. To assess duration of standard of care first line systemic therapy received from time of response assessment in Cohort B. (Observational Cohort)

BANKING OBJECTIVE:

I. To bank specimens for future correlative studies.

OUTLINE:

STEP 1: Patients receive physician's choice of HER2-targeted systemic therapy according to National Comprehensive Cancer Network (NCCN)/American Society of Clinical Oncology (ASCO) guidelines until completion of at least 12 weeks (4 cycles) or up to 24 weeks (8 cycles) of HER2-targeted therapy prior to Step 2 registration. Patients with brain metastases may also undergo stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) at the discretion of the treating physician.

STEP 2: Patients with partial or complete response in the breast following completion of Step 1 are assigned to Cohort A. Patients with clinically stable or progressive disease following completion of Step 1 are assigned to Cohort B.

COHORT A: Patients are randomized to 1 of 2 arms.

ARM 1:

LOCOREGIONAL THERAPY: Patients undergo breast surgery (either breast conserving therapy or total mastectomy) within 4-6 weeks of completion of Step 1 systemic therapy. Within 8 weeks of breast surgery, patients undergo locoregional radiation therapy (RT) to the breast, with or without RT to the breast/chest wall and/or regional lymph nodes, over 5-16 fractions. Patients may undergo RT boost to the lumpectomy bed over 4-5 fractions at the discretion of the treating physician.

STEREOTACTIC BODY RADIATION THERAPY (SBRT): Within 4-6 weeks of completion of locoregional therapy, patients undergo SBRT, with or without concurrent adjuvant therapy (pertuzumab and trastuzumab, or trastuzumab emtansine [T-DM1], or trastuzumab deruxtecan [T-DXd] with or without pertuzumab), to all targetable metastatic lesions every other day for 1, 3, or 5 fractions over a maximum of 3 weeks.

POST-LOCOREGIONAL THERAPY AND SBRT: Following recovery from surgery, patients resume systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines for at least 1 year in the absence of disease progression or unacceptable toxicity. Patients who are estrogen receptor positive may also receive endocrine therapy, with or without CDK4/6 inhibitors, at the discretion of the treating physician for at least 5 years, in the absence of disease progression or unacceptable toxicity.

ARM 2: Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines for at least 1 year in the absence of disease progression or unacceptable toxicity. Patients may receive locoregional therapy and/or SBRT according to standard of care only if required for palliative purposes.

COHORT B: Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines in the absence of disease progression or unacceptable toxicity.

All patients also undergo echocardiography (ECHO), magnetic resonance imaging (MRI), mammography, ultrasound, computed tomography (CT), and/or positron emission tomography (PET)/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.

After completion of study treatment, patients registered to Step 2 are followed up for 10 years.

03

Conditions studied

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic HER2-Positive Breast Carcinoma
  • Oligometastatic Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • REGISTRATION STEP 1 - SCREENING \& INITIAL TREATMENT:
  • Participants must have confirmed de novo (i.e. American Joint Committee on Cancer [AJCC] stage IV, no prior history of breast cancer) + breast cancer with 1 to 5 distant metastatic lesions (oligometastatic). Metastatic breast cancer must be histologically confirmed through of a distant metastatic lesion unless it is not feasible or safe to biopsy a metastatic lesion, then there must be unequivocal evidence of metastasis on imaging and laboratory studies. HER2+ status must be confirmed in the breast tumor and distant metastatic site as defined per NCCN guidelines version 4.2025

    • NOTE: If HER2 positivity at metastatic site is equivocal due to limitations in HER2 analysis in bone, or it is not feasible or safe to biopsy the metastatic lesion, then HER2 positivity based on breast tumor only is acceptable. If there is no breast lesion, HER2+ must be confirmed in at least one metastatic site
  • Participants with are eligible if they meet all of the following criteria at baseline:

    • There are 5 or fewer intracranial lesions
    • Each intracranial lesions is no larger than 2cm in longest dimension
    • NOTE: The brain is counted as 1 distant site towards the oligometastatic definition. Brain imaging is not required for participants who have no neurological signs or symptoms suggestive of central nervous system (CNS) involvement; however, assessment of neurological symptoms and brain MRI is strongly encouraged to rule out CNS disease
  • Participants must have no known
  • Participants must meet one of the following criteria prior to Step 1 registration:

    • Treatment naïve and planning to initiate standard of care systemic HER2+ targeted treatment OR
    • Have already initiated standard of care systemic HER2+ targeted treatment and have completed at least one (≥ 1) but no more than three (≤ 3) cycles prior to enrollment, without progression

      • NOTE: Standard of care scans for baseline disease assessment must have been performed within 28 days prior to initiation of treatment
  • Participants must not be receiving or planning to receive any systemic therapy during study before disease progression
  • Participants must not have received whole brain irradiation

    • NOTE: Participants with up to five brain metastases may have received SRS/SRT either before or after initiation of systemic therapy. If lesions are small and asymptomatic and the participant is receiving CNS penetration they may be managed with observation
  • Participants must be ≥ 18 years old at the time of registration
  • Participants must have Zubrod performance status of 0-2
  • Participants with known (HIV)-infection must be on effective anti-retroviral therapy and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration
  • Participants must be able to safely receive the physician's choice of standard of care systemic HER2+ targeted treatment per the current Food and Drug Administration (FDA)-approved package insert(s), treating physician's discretion, and institutional guidelines
  • Participants must be candidates for definitive surgical and radiotherapeutic management of locoregional disease opinion per the discretion of the treating physician
  • Participants must be able to receive ablative dose stereotactic body radiation therapy (SBRT) to all metastatic lesions identified at baseline, in the opinion of the treating physician
  • Participants must be offered the opportunity to participate in specimen banking
  • NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

    • Participants must be informed of the investigational nature of this study and must sign and give in accordance with institutional and federal guidelines For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and CIRB regulations
  • REGISTRATION STEP 2 - COHORT ASSIGNMENT AND RANDOMIZATION:
  • COHORT A: Participants must be registered to Step 2 within 14 days of staging scans performed after completing Step 1 systemic therapy
  • COHORT A: Participants must have standard of care (SOC) staging scans and breast imaging performed following 12-24 weeks (minimum of 4 cycles) of initial systemic therapy and within 14 days prior to Step 2 registration
  • COHORT A: Participants must have experienced partial or complete response in the breast (in the opinion of the treating physician) following 12-24 weeks of initial systemic therapy based on staging scans performed within 14 days prior to Step 2 registration

    • Participants with breast lesion(s) at diagnosis must have a clinical response on breast imaging per the treating physician
    • Metastatic lesions, as assessed by (RECIST) and bone response criteria, must have at least stable disease
    • Brain metastases treated with SRS/SRT must have at least stable disease as per Response Assessment in Neuro-Oncology Brain Metastases (RANO BM) and must not require treatment
    • Participants with no known breast lesions at diagnosis must have at least partial response in the metastatic sites as assessed by RECIST and bone response criteria
    • NOTE: The same imaging modality must be used as in Step 1
  • COHORT A: Participants must be eligible for definitive surgical and radiotherapeutic management of locoregional disease per the discretion of the treating physician
  • COHORT A: Participants must not have metastatic lesions that are not amenable to ablative dose stereotactic body radiation therapy (SBRT)

    • Lung lesions that completely resolve after systemic therapy will not be targeted with SBRT, as it is not possible to achieve dose build-up
    • The development of new sclerotic bone lesions after systemic therapy is not to be interpreted as disease progression, and all such lesions should be targeted with SBRT
  • COHORT B: Participants must be registered to Step 2 within 14 days of staging scans performed after completing Step 1 systemic therapy
  • COHORT B: Participants must have standard of care (SOC) staging and breast imaging performed following 12-24 weeks (minimum of 4 cycles) of initial systemic therapy and within 14 days prior to Step 2 registration
  • COHORT B: Participants must experience clinically stable disease or progression following 12-24 weeks (minimum of 4 cycles) of initial systemic therapy and within 14 days prior to Step 2 registration

    • Participants must have progression in metastatic lesions as assessed by RECIST and bone response criteria or may have stable disease in metastatic lesions by RECIST and bone response criteria if there is progression or no clinical response in the breast
    • Participants with known breast lesion must have progression or no clinical response on breast imaging as per the treating physician
    • NOTE: The same modality must be used as in Step 1
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
562 participants (estimated)

Study arms

  • Experimental
    Step 1 (HER2-targeted systemic therapy, STS/SRT)

    Patients receive physician's choice of HER2-targeted systemic therapy according to NCCN/ASCO guidelines until completion of at least 12 weeks (4 cycles) or up to 24 weeks (8 cycles) of HER2-targeted therapy prior to Step 2 registration. Patients with brain metastases may also undergo SRS/SRT at the discretion of the treating physician. All patients also undergo ECHO, MRI, mammography, ultrasound, CT, and/or PET/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Echocardiography Test · Drug: HER2-targeted Therapy · Procedure: Magnetic Resonance Imaging · Procedure: Mammography · Procedure: Positron Emission Tomography · Radiation: Stereotactic Radiosurgery · Procedure: Ultrasound Imaging

  • Experimental
    Step 2 Cohort A, Arm 1 (locoregional, SBRT, systemic therapy)

    See Detailed Description.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Breast Conservation Treatment · Procedure: Computed Tomography · Drug: Cyclin-Dependent Kinase 4 Inhibitor · Drug: Cyclin-Dependent Kinase 6 Inhibitor · Procedure: Echocardiography Test · Drug: Hormone Therapy · Procedure: Magnetic Resonance Imaging · Procedure: Mammography · Biological: Pertuzumab · Procedure: Positron Emission Tomography · Radiation: Radiation Boost · Radiation: Radiation Therapy · Radiation: Stereotactic Body Radiation Therapy · Drug: Taxane Compound · Procedure: Total Mastectomy · Biological: Trastuzumab · Biological: Trastuzumab Deruxtecan · Biological: Trastuzumab Emtansine · Procedure: Ultrasound Imaging

  • Experimental
    Step 2 Cohort A, Arm 2 (systemic therapy)

    Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines for at least 1 year in the absence of disease progression or unacceptable toxicity. Patients may receive locoregional therapy and/or SBRT according to standard of care only if required for palliative purposes. All patients also undergo ECHO, MRI, mammography, ultrasound, CT, and/or PET/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Breast Conservation Treatment · Procedure: Computed Tomography · Procedure: Echocardiography Test · Procedure: Magnetic Resonance Imaging · Procedure: Mammography · Biological: Pertuzumab · Procedure: Positron Emission Tomography · Radiation: Radiation Boost · Radiation: Radiation Therapy · Radiation: Stereotactic Body Radiation Therapy · Drug: Taxane Compound · Procedure: Total Mastectomy · Biological: Trastuzumab · Biological: Trastuzumab Deruxtecan · Biological: Trastuzumab Emtansine · Procedure: Ultrasound Imaging

  • Experimental
    Step 2 Cohort B (systemic therapy)

    Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines in the absence of disease progression or unacceptable toxicity. All patients also undergo ECHO, MRI, mammography, ultrasound, CT, and/or PET/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Echocardiography Test · Procedure: Magnetic Resonance Imaging · Procedure: Mammography · Biological: Pertuzumab · Procedure: Positron Emission Tomography · Biological: Trastuzumab · Biological: Trastuzumab Deruxtecan · Biological: Trastuzumab Emtansine · Procedure: Ultrasound Imaging

Interventions

  • ProcedureBiopsy Procedure

    Undergo biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBreast Conservation Treatment

    Undergo breast conserving therapy

    Also known as: BCS, BCT, Breast Conserving Surgery/Lumpectomy, Breast-Conserving Surgery, breast-sparing surgery

  • ProcedureComputed Tomography

    Undergo CT and/or PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • DrugCyclin-Dependent Kinase 4 Inhibitor

    Given CDK4/6 inhibitor

    Also known as: CDK4 Inhibitor

  • DrugCyclin-Dependent Kinase 6 Inhibitor

    Given CDK4/6 inhibitor

    Also known as: CDK6 Inhibitor

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • DrugHER2-targeted Therapy

    Receive HER2-targeted systemic therapy

  • DrugHormone Therapy

    Given endocrine therapy

    Also known as: Chemotherapy-Hormones/Steroids, Endocrine Therapy, Hormonal, Hormonal Therapy, Hormonal Treatment, hormone treatment, Hormones

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedureMammography

    Undergo mammography

    Also known as: MG

  • BiologicalPertuzumab

    Given pertuzumab

    Also known as: 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Pertuzumab-dpzb, Poherdy, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • RadiationRadiation Boost

    Undergo RT boost

    Also known as: BOOST, Boost Radiation, Boost Radiation Therapy, Boost Radiotherapy, Radiation Therapy Boost, Radiotherapy Boost

  • RadiationRadiation Therapy

    Undergo RT

    Also known as: Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

  • RadiationStereotactic Body Radiation Therapy

    Undergo SBRT

    Also known as: SABR, SBRT, Stereotactic Ablative Body Radiation Therapy

  • RadiationStereotactic Radiosurgery

    Undergo SRS/SRT

    Also known as: SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery

  • DrugTaxaneStudies of TaxaneTaxane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given taxane therapy

    Also known as: taxane, Taxanes

  • ProcedureTotal Mastectomy

    Undergo total mastectomy

    Also known as: Simple Mastectomy

  • BiologicalTrastuzumab

    Given trastuzumab

    Also known as: ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac

  • Given T-DXd

    Also known as: DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516

  • BiologicalAdo-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given T-DM1

    Also known as: Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate

  • ProcedureUltrasound Imaging

    Undergo ultrasound

    Also known as: 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US

06

What researchers measure

Primary outcomes

  1. Overall survival (OS) (Cohort A)

    The primary analysis to evaluate the primary objective in the randomized cohort will be an intent-to treat (ITT) comparison of Arm 1 versus Arm 2 using a stratified log-rank test including all randomized, eligible participants. The hazard ratio and 95% confidence interval (CI) will be estimated by Cox regression including the stratification factors as variables in the model. Primary analyses will be repeated among individuals with brain metastases to understand whether the effect of the intervention differs in this subgroup.

    Time frame: From date of Step 2 registration to date of death, assessed up to 10 years

  2. Progression-free survival (PFS) (Observational Cohort B)

    In the observational cohort, the primary objective will be evaluated by estimating 3- and 5-year survival and corresponding 95% CIs using the Kaplan-Meier estimator. All analyses in the observational cohort will be descriptive. Primary analyses will be repeated among individuals with brain metastases to understand whether the effect of the intervention differs in this subgroup.

    Time frame: From date of Step 2 registration to date of first documentation of progression or recurrence or death, assessed at 3 and 5 years

  3. Overall survival (Observational Cohort B)

    In the observational cohort, the primary objective will be evaluated by estimating 3- and 5-year survival and corresponding 95% CIs using the Kaplan-Meier estimator. All analyses in the observational cohort will be descriptive. Primary analyses will be repeated among individuals with brain metastases to understand whether the effect of the intervention differs in this subgroup.

    Time frame: From date of Step 2 registration to date of death, assessed at 3 and 5 years

Secondary outcomes

  1. Progression free survival (Cohort A)

    The primary analysis will be an ITT comparison of Arm 1 versus Arm 2 using a stratified log-rank test including all randomized, eligible participants. The hazard ratio and 95% CI will be estimated by Cox regression including the stratification factors as variables in the model. In addition to the primary analyses, will estimate PFS at 3 years and 5 years in Arm 1 and Arm 2 and corresponding 95% CIs using the Kaplan-Meier estimator.

    Time frame: From date of Step 2 registration to date of first documentation of progression or recurrence or death, assessed at 3 and 5 years and then up to 10 years

  2. Overall survival (Cohort A)

    The primary analysis will be an ITT comparison of Arm 1 versus Arm 2 using a stratified log-rank test including all randomized, eligible participants. The hazard ratio and 95% CI will be estimated by Cox regression including the stratification factors as variables in the model. In addition to the primary analyses, will estimate OS at 3 years and 5 years in Arm 1 and Arm 2 and corresponding 95% CIs using the Kaplan-Meier estimator.

    Time frame: From date of Step 2 registration to date of death, assessed at 3 and 5 years and then up to 10 years

  3. Duration of standard of care first line systemic therapy (Cohort B)

    Time frame: From time of response assessment at end of Step 1 up to 10 years

07

Study locations

59 of 59 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for May 2032, 62 months later.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 62 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 11, 2026
StartEst.
Mar 9, 2027
Primary completionEst.
May 31, 2032
CompletionEst.
May 31, 2033
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
59 sites added — first site in United States
Show 59 added (59 United States)
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro · Jonesboro, United States
  • Smilow Cancer Hospital-Derby Care Center · Derby, United States
  • Smilow Cancer Hospital Care Center-Fairfield · Fairfield, United States
  • Smilow Cancer Hospital Care Center at Greenwich · Greenwich, United States
  • Smilow Cancer Hospital Care Center - Guilford · Guilford, United States
  • Smilow Cancer Hospital-Hamden Care Center · Hamden, United States
  • Smilow Cancer Center/Yale-New Haven Hospital · New Haven, United States
  • Yale University · New Haven, United States
  • Yale-New Haven Hospital North Haven Medical Center · North Haven, United States
  • Smilow Cancer Hospital Care Center at Long Ridge · Stamford, United States
  • Smilow Cancer Hospital-Torrington Care Center · Torrington, United States
  • Smilow Cancer Hospital Care Center-Trumbull · Trumbull, United States
  • Smilow Cancer Hospital-Waterbury Care Center · Waterbury, United States
  • Smilow Cancer Hospital Care Center - Waterford · Waterford, United States
  • Orlando Health Cancer Institute · Orlando, United States
  • OSF Saint Joseph Medical Center · Bloomington, United States
  • Illinois CancerCare-Bloomington · Bloomington, United States
  • Illinois CancerCare-Canton · Canton, United States
  • Illinois CancerCare-Carthage · Carthage, United States
  • Cancer Care Specialists of Illinois - Decatur · Decatur, United States
  • Decatur Memorial Hospital · Decatur, United States
  • Illinois CancerCare-Eureka · Eureka, United States
  • Illinois CancerCare-Galesburg · Galesburg, United States
  • Illinois CancerCare-Kewanee Clinic · Kewanee, United States
  • Illinois CancerCare-Macomb · Macomb, United States
  • Cancer Care Center of O'Fallon · O'Fallon, United States
  • HSHS Saint Elizabeth's Hospital · O'Fallon, United States
  • Illinois CancerCare-Ottawa Clinic · Ottawa, United States
  • Illinois CancerCare-Pekin · Pekin, United States
  • Illinois CancerCare-Peoria · Peoria, United States
  • …and 29 more on the registry record
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    59 sites added — first site in United States
    Show 59 added (59 United States)
    • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro · Jonesboro, United States
    • Smilow Cancer Hospital-Derby Care Center · Derby, United States
    • Smilow Cancer Hospital Care Center-Fairfield · Fairfield, United States
    • Smilow Cancer Hospital Care Center at Greenwich · Greenwich, United States
    • Smilow Cancer Hospital Care Center - Guilford · Guilford, United States
    • Smilow Cancer Hospital-Hamden Care Center · Hamden, United States
    • Smilow Cancer Center/Yale-New Haven Hospital · New Haven, United States
    • Yale University · New Haven, United States
    • Yale-New Haven Hospital North Haven Medical Center · North Haven, United States
    • Smilow Cancer Hospital Care Center at Long Ridge · Stamford, United States
    • Smilow Cancer Hospital-Torrington Care Center · Torrington, United States
    • Smilow Cancer Hospital Care Center-Trumbull · Trumbull, United States
    • Smilow Cancer Hospital-Waterbury Care Center · Waterbury, United States
    • Smilow Cancer Hospital Care Center - Waterford · Waterford, United States
    • Orlando Health Cancer Institute · Orlando, United States
    • OSF Saint Joseph Medical Center · Bloomington, United States
    • Illinois CancerCare-Bloomington · Bloomington, United States
    • Illinois CancerCare-Canton · Canton, United States
    • Illinois CancerCare-Carthage · Carthage, United States
    • Cancer Care Specialists of Illinois - Decatur · Decatur, United States
    • Decatur Memorial Hospital · Decatur, United States
    • Illinois CancerCare-Eureka · Eureka, United States
    • Illinois CancerCare-Galesburg · Galesburg, United States
    • Illinois CancerCare-Kewanee Clinic · Kewanee, United States
    • Illinois CancerCare-Macomb · Macomb, United States
    • Cancer Care Center of O'Fallon · O'Fallon, United States
    • HSHS Saint Elizabeth's Hospital · O'Fallon, United States
    • Illinois CancerCare-Ottawa Clinic · Ottawa, United States
    • Illinois CancerCare-Pekin · Pekin, United States
    • Illinois CancerCare-Peoria · Peoria, United States
    • …and 29 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07578116
Responsible party
Sponsor
First posted
May 11, 2026
Start date
Mar 9, 2027 (estimated)
Primary completion
May 31, 2032 (estimated)
Completion
May 31, 2033 (estimated)
Last update
Oct 13, 2026

Study contacts

Mariya Rozenblit
principal investigator · SWOG Cancer Research Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion